| |
|
Product Name:
|
NYCA04
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Protozoa Classification: Trichomonadidae, Trichomonas
Species: Trichomonas vaginalis
Strain: NYCA04
|
|
Additional Information:
|
T. vaginalis is the most common non-viral, sexually transmitted parasite in humans and causative agent of trichomoniasis.2,3,4,5 Metronidazole is the drug of choice for treatment, however resistance to this antibiotic has been observed in some clinical cases.2,3 The unique population structure of this genetically diverse parasite consists of two genotypes, 1 and 2, present in equal proportions world-wide.3 These genotypes differ in the rate at which they harbor the T. vaginalis virus (TVV), a non-segmented dsRNA virus of the family Totiviridae involved in T. vaginalis virulence and disease pathogenesis, and in their sensitivity to metronidazole.3,4,5 Infection of T. vaginalis with TVV is associated primarily with genotype type 1 strains and increased susceptibility to metronidazole.2,4
|
|
Material Provided:
|
Each vial contains approximately 0.5 mL of cells in cryopreservative [5% dimethylsulfoxide (DMSO)]. Please refer to the Certificate of Analysis for the specific culture media used for each lot and to the Appendix for cryopreservation instructions.
|
|
Packing/Storage:
|
NR-58890 was packaged aseptically in cryovials and is provided frozen on dry ice. The product should be stored at -130°C or colder, preferably in the vapor phase of a liquid nitrogen freezer. If liquid nitrogen storage facilities are not available, frozen cryovials may be stored at -70°C or colder for approximately one week.
Note: Do not under any circumstances store vials at temperatures warmer than -70°C. Storage under these conditions will result in the death of the culture.
To ensure the highest level of viability, the culture should be initiated immediately upon receipt. Any warming of the product during shipping and transfer must be avoided, as this will adversely affect the viability of the product. For transfer between freezers and for shipping, the product may be placed on dry ice for brief periods, although use of a portable liquid nitrogen carrier is preferred. Please read the following recommendations prior to using this material.
|
|
Growth Conditions:
|
Media:
Modified Trypticase – Yeast – Maltose (TYM) Basal medium supplemented with 10% heat-inactivated horse serum (HIHS) and 0.71% iron (Appendix) or equivalent
Incubation:
Temperature: 35°C
Atmosphere: Microaerophillic
Propagation:
1. To establish a culture from the frozen state, place a vial in a 35°C to 37°C water bath. Thawing time is approximately 2 to 3 minutes. Do not agitate the vial. Do not leave the vial in the water bath after it is thawed.
2. Transfer the vial contents to a 16 × 125 mm screw-capped borosilicate glass test tube containing 13 mL of growth medium.
3. Screw the cap on tightly and incubate at a 15° horizontal slant at 35°C. Observe the culture daily and subculture when peak density is observed.
Maintenance:
1. When the culture is at or near peak density, ice the culture for 10 minutes and gently invert 20 times.
2. Add 12 mL of freshly prepared growth media to two sterile tubes.
3. Transfer every 2 to 3 days, as needed. Note that the transfer interval should be determined empirically as it is dependent on the quantity of the inoculum.
4. Aseptically transfer a 100 µL to 250 µL aliquot of the Trichomonas culture to the tubes prepared in step 2.
5. Screw the cap on tightly and incubate at a 15° horizontal slant at 35°C. Observe the culture daily and subculture when peak density is observed.
Please refer to the Appendix for cryopreservation instructions.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Carlton, J., Personal Communication.
2. Bradic, M., et al. “Genetic Indicators of Drug Resistance in the Highly Repetitive Genome of Trichomonas vaginalis.” Genome Biol. Evol. 9 (2017): 1658-1672. PubMed: 28633446.
3. Conrad, M. D., et al. “Extensive Genetic Diversity, Unique Population Structure and Evidence of Genetic Exchange in the Sexually Transmitted Parasite Trichomonas vaginalis.” PLoS Negl. Trop. Dis. 6 (2012): e1573. PubMed: 22479659.
4. Graves, K. J., et al. “Trichomonas vaginalis: A Review of the Literature.” Int. J. STD. AIDS 30 (2019): 496-504. PubMed: 30626281.
5. Edwards, T., et al. “Trichomonas vaginalis: Clinical Relevance, Pathogenicity and Diagnosis.” Crit. Rev. Microbiol. 42 (2016): 406-417. PubMed: 25383648.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through the BEI Resources, NIAID, NIH: Trichomonas vaginalis, Strain NYCA04, NR-58890.”
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|